Venlafaxine Discontinuation Protocol
For adults discontinuing venlafaxine, reduce the dose by 37.5-75mg every 4-7 days if on the medication less than 6 months, or by 37.5mg every 1-2 weeks if on it longer than 6 months or at doses above 150mg, with the entire taper typically requiring 4-12 weeks depending on starting dose and treatment duration. 1
Tapering Schedule Based on Treatment Duration
Short-Term Use (< 6 months)
- Reduce venlafaxine by 37.5-75mg every 4-7 days 1
- Monitor closely for withdrawal symptoms at each step 1
Long-Term Use (> 6 months) or High Dose (> 150mg)
- Reduce by 37.5mg every 1-2 weeks rather than weekly 1
- For patients on 225mg daily, expect a minimum 6-8 week taper 1
- Complete discontinuation typically requires 4-12 weeks, with patients on higher doses or longer duration expecting the longer end of this range 1
Critical caveat: Venlafaxine has an exceptionally high risk of discontinuation syndrome compared to other antidepressants due to its short half-life. 2, 3 Withdrawal symptoms can occur within hours of a missed dose 2, 3, and may be severe enough to resemble stroke symptoms 3. This makes adherence to the tapering schedule absolutely essential.
Managing Withdrawal Symptoms
If Withdrawal Symptoms Emerge
- Slow or pause the taper rather than adding additional medications 1
- Do not proceed to the next dose reduction until symptoms resolve 1
Symptomatic Management
- Nausea: Ondansetron 4-8mg as needed 1
- Headache: Acetaminophen or NSAIDs 1
- Severe insomnia: Sleep hygiene education first; consider trazodone 25-50mg at bedtime only if severe 1
Alternative Strategy for Difficult Cases
- If standard tapering fails due to severe withdrawal symptoms, consider switching to fluoxetine (which has a longer half-life) to facilitate discontinuation 4
- This "fluoxetine-mediated discontinuation" is a simple, effective, and inexpensive method for patients suffering from withdrawal symptoms 4
Monitoring Requirements
Frequency of Assessment
- Assess withdrawal symptoms and psychiatric status at least weekly during active taper 1
- Increase contact frequency during difficult phases 1
Specific Parameters to Monitor
- Suicidal ideation, particularly in patients under age 25 1, 5
- Blood pressure changes, as venlafaxine can cause sustained hypertension and withdrawal may cause fluctuations 1
- Emergence of agitation, irritability, unusual behavior changes 5
- Common withdrawal symptoms: headache, nausea, fatigue, dizziness, dysphoria 2
Important warning: The FDA mandates close monitoring for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of therapy or at times of dose changes (including decreases during tapering). 5
Special Populations
Elderly Patients
- Use more gradual taper with smaller dose reductions (18.75-37.5mg every 2 weeks) 1
- Monitor more closely for dizziness and fall risk during withdrawal 1
Patients with Cardiac Disease
Patients with History of Mental Health Issues
- Screen for bipolar disorder before initiating any antidepressant treatment, as treating a depressive episode with an antidepressant alone may precipitate a manic episode 5
- Maintain heightened vigilance for return of depressive symptoms during taper 1
Common Pitfalls to Avoid
- Never stop venlafaxine abruptly - this can cause severe withdrawal syndrome within hours 5, 2, 3
- Do not underestimate withdrawal severity - symptoms may be intense enough to resemble neurological emergencies like stroke 3
- Warn patients about driving risks - withdrawal symptoms can affect motor and coordination skills within hours of a missed dose 6
- Do not rush the taper - patients should adhere to the schedule strictly or risk severe discontinuation symptoms 1, 6
Expected Timeline
- Minimum taper duration: 4 weeks for lower doses and shorter treatment duration 1
- Expected taper duration: 6-8 weeks for 225mg daily dose 1
- Maximum taper duration: 12 weeks for highest doses and longest treatment duration 1
The medication should be tapered as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with significant symptoms. 5